Latest Articles
-
What Will Drive Medtronic’s Near Term Growth
Medtronic (NYSE:MDT) recently posted its Q1 FY19 numbers, which were better than street estimates, led by a strong growth in the diabetes business. The company also revised its guidance upward, and expects strong growth in diabetes for the full ...
-
How Surgical And Patient Monitoring Products Are Driving Medtronic’s Growth
The Surgical and Patient Monitoring business has been a cornerstone of Medtronic ‘s (NYSE:MDT) growth. The company has grown both organically and inorganically in this market. We estimate that this business constitutes nearly 40% of Medtro...
-
Medtronic Earnings: Disappointing Q2’17 Results Drive Down The Company’s Stock Price
Medtronic (NYSE: MDT) reported its Q2’17 earnings on November 22nd. (Fiscal years end with April.) The company’s stock price has plunged by 8% post the earnings announcement, due to lackluster performance. Medtronic’s revenues i...
-
Medtronic Pre-Earnings: Growth To Be Driven By Cardiovasuclar And Diabetes Segments
Medtronic (NYSE: MDT) is set to report its Q2’17 earnings on November 22nd. (Fiscal years ending with April.) We can expect Medtronic to report a decent quarter, driven by revenue growth from a strong portfolio of products in both the Diabe...
-
Assessing The Impact: Medtronic’s MiniMed 670G Gets FDA Nod
Medical technology player Medtronic (NYSE: MDT) recently received U.S. FDA nod for its MiniMed 670G system, which is the first Hybrid Closed Loop insulin delivery system. This is a significant news as far as the company’s diabetes segment is conc...
-
Medtronic’s Futuristic Approach In Diabetes
In a relatively somber quarter recently reported by Medtronic (NYSE: MDT), the diabetes segment posted strong performance. It is the company’s smallest business segment, contributing about 7% to the firm’s revenue and close to 5% to i...
-
What Should Investors Make Of Medtronic’s Investment In Mazor Robotics?
Medtronic (NYSE: MDT) recently made second tranche of $20 million equity investment in Mazor Robotics (NASDAQGM:MZOR), raising its ownership to about 7.27%. In May this year, the company had invested $11.9 million for about 3.4% ownership stake ...
-
How Did Medtronic Fare In Q1’17 Earnings?
Medical technology company Medtronic (NYSE: MDT) reported its Q1 earnings for fiscal 2017 on August 25th. (Fiscal years end with April.) The Diabetes segment was the best performer with its revenue growing by 2% on year-over-year basis, while oth...
-
Medtronic’s Earnings Preview: What To Expect
Medtronic (NYSE: MDT) will report its Q1 earnings for fiscal year 2017 on August 25 th . Revenue from operations is expected to have grown by mid-single digits in Q1. Strong adoption of Micra TPS, MRI-implantable defibrillator, MiniMed and the la...
-
How Has Medtronic’s Revenue And Gross Profit Changed Over The Last Five Years?
See More at Trefis | View Interactive Institutional Research (Powered by Trefis) Get Trefis Technology
-
What Is Medtronic’s Fundamental Value Based On Expected 2016 Results?
See More at Trefis | View Interactive Institutional Research (Powered by Trefis) Get Trefis Technology
-
How Has Medtronic’s Revenue Mix Changed In The Last five Years?
Following the Covidien acquisition, the Surgical and Patient Monitoring products segment has become the most important segment for Medtronic (NYSE:MDT). This comes from the fact that, apart from certain vascular and surgical products, there was...
-
Why Is Medtronic Acquiring Heartware?
Medtronic (NYSE:MDT) said Monday that it had entered into an agreement to acquire Heartware in a $1.1 billion deal which will help it expand its current portfolio of heart products. According to the terms of the deal, Medtronic will pay $58 per ...
-
What Is Medtronic’s Revenue And Gross Profit Breakdown?
See More at Trefis | View Interactive Institutional Research (Powered by Trefis) Get Trefis Technology
-
How Can Medtronic Gain With The Development Of Hybrid Closed Loop System For Type-1 Diabetes?
At the forefront of the development of a hybrid closed loop system for controlling type-1 diabetes is Medtronic (NYSE:MDT), which is likely to launch the product by as soon as 2017. As compared to a conventional insulin pump, the hybrid closed...
